CPT code 87517 represents a molecular diagnostic assay that quantifies hepatitis B virus (HBV) using a nucleic acid probe technique. This test is clinically important for identifying and monitoring active HBV infection, informing clinical management of acute and chronic liver disease, and guiding public health surveillance. Nationally, HBV testing supports prevention of transmission and appropriate linkage to care.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 87517 covers, the clinical context for its use, and the typical laboratory setting where the service is performed. The publication also summarizes common billing considerations, relevant modifiers (listed separately), and what to expect in payer coverage patterns.

This summary provides benchmarks and policy-relevant points for stakeholders interested in laboratory reimbursement, coding compliance, and service utilization for HBV molecular testing. Data not available in the input is noted where applicable, and the focus remains on the clinical and billing definition of CPT code 87517 for a national audience.